Adalimumab biosimilar (Innovent Biologics)

阿达木单抗生物类似药（信达生物）

Report date: 2022/06/02 15:34:52

Base Information

Drug NameAdalimumab biosimilar (Innovent Biologics)
Drug Alias NameAdalimumab (Innovent Biologics)抗TNF-α单克隆抗体（Innovent Biologics）阿达莫单抗生物仿制药（Innovent Biologics）Adalimumabum (Innovent Biologics)阿达木单抗生物仿制药（Innovent Biologics） +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisPsoriasisUveitis +[8] 
Global Approved IndicationsPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing
Approved Indications in ChinaPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing
Original Approved Country/TerritoryMainland China
Original Approved Date2020/09/02
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesInnovent Biologics(Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInnovent Biologics(Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisUveitis +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB04
Related LinksN/A